Skip to main content
EJNMMI Research
Fig. 4 | EJNMMI Research

Fig. 4

From: In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

Fig. 4

Discrepancy of [177Lu]Lu-PP-F11N and [68Ga]Ga-DOTATOC uptake in patient 5. Axial CT (A, D), SPECT/CT (B), PET/CT (E) and MIP (C, F) of patient 5. No visible uptake of [177Lu]Lu-PP-F11N in SPECT/CT (white arrow, B, with Entresto® premedication) and MIP (C). Intense uptake of [68Ga]Ga-DOTATOC in multiple lytic bone metastases (white and black arrowheads, E, F. u: urine contamination

Back to article page